On March 16, 2026, HCA Healthcare (NYSE: HCA) presented at the Oppenheimer 36th Annual Healthcare MedTech & Services Conference. Executives outlined a strong 2025 performance and shared their strategic vision for 2026. They addressed anticipated headwinds, including shifts in Health Insurance Exchange (HIX) volume, while expressing confidence in the company’s long-term growth trajectory.
Overview: A Strong 2025 Performance
HCA Healthcare delivered impressive results in 2025. The company managed 47 million patient encounters across 43 domestic markets. Furthermore, every domestic division posted positive adjusted admission growth year-over-year. Collectively, these gains drove a 2.4% overall admission growth for the year.
Additionally, HCA improved its EBITDA margin by 90 basis points, reaching 20.6%. EVP and COO Jon Foster noted that disciplined expense management — particularly in labor and supplies — played a critical role in this achievement. The company enters 2026 with strong momentum and a clear strategic agenda.
Financial Highlights That Matter
HCA’s 2025 financials reflect a resilient and well-managed health system. Key metrics include:
- Adjusted admission growth: 2.4%
- EBITDA margin: 20.6% (up 90 basis points)
- Cash flow from operations: $12.6 billion
- Share repurchases: $10 billion
- Capital expenditures: $5 billion
Looking ahead, HCA projects cash flow from operations of $12 to $13 billion in 2026. Moreover, the company plans to increase capital expenditures to $5–$5.5 billion for the year. This robust cash generation gives management significant flexibility to pursue growth and return value to shareholders.
Operational Updates and Network Expansion
Outpatient Growth Strategy
HCA is actively expanding its outpatient footprint. Currently, each hospital connects to an average of 14 outpatient sites of care. However, the company plans to grow that number to at least 20 per hospital. This expansion supports a broader goal of achieving a 30% composite market share by the end of the decade.
To fund this growth, HCA has approximately $7 billion in capital projects in flight. These projects will come online within the next 24 to 36 months. Together, they target both inpatient capacity and outpatient network development — ensuring patients receive care where, when, and how they prefer.
Labor Market Stability
HCA has reached a significantly more stable labor environment compared to the pandemic era. Turnover rates have fallen back to pre-pandemic levels. Contract labor costs now represent just 4.3% of salary, wages, and benefits — nearly matching pre-pandemic figures. Nevertheless, the company does face elevated cost pressure in hospital-based physician services, where high single-digit inflation is expected in 2026.
The HIX Headwind: What Investors Must Know
One of the most closely watched topics at the conference was the Health Insurance Exchange (HIX) impact. In 2025, HIX represented approximately 8% of admissions and 10% of revenue for HCA. Consequently, changes in this segment carry significant financial implications.
HCA projects a $600 million to $900 million headwind in 2026 due to reduced HIX volume. The company estimates a 15%–20% decline in HIX volume. Of those lost enrollees, about 15%–20% will transition to employer-sponsored insurance — which actually benefits HCA. The remainder will move to uninsured status, with lower expected utilization.
Importantly, HCA monitored enrollment data closely. Although national exchange enrollment declined roughly 5%, HCA’s states saw approximately a 4% decline — better than initial expectations. Management will assess effectuation rates and metal-tier shifts throughout Q1 2026 before providing further guidance.
AI and Digital Innovation at HCA
HCA is actively integrating artificial intelligence across three strategic domains: administrative, operational, and clinical.
On the administrative side, AI tools help manage insurer denials, generate appeal letters, and summarize medical records for physician review. This investment has measurably reduced the financial impact of rising denials across the industry.
From an operational perspective, HCA has deployed AI-driven demand forecasting tools across many hospitals. These tools match staffing and scheduling to predicted patient volume, improving efficiency and reducing waste.
In the clinical domain, the company is developing AI-powered shift handoff tools for nurses. Given that thousands of handoffs occur daily across the enterprise, even modest improvements can drive significant patient safety gains. HCA pilots innovations through its Innovation Hub hospitals before scaling them enterprise-wide.
Capital Deployment and Share Repurchases
HCA follows a disciplined, four-pillar capital allocation strategy: capital expenditures, mergers and acquisitions (M&A), dividends, and share repurchases.
The company repurchased $10 billion in shares in 2025. Moreover, the board authorized another $10 billion in buybacks. Management expects to deploy a majority of that authorization in 2026. Meanwhile, the board also approved a dividend increase in January 2026, reflecting ongoing confidence in cash flow generation.
On the M&A front, HCA acquired two hospitals in 2025 and continues to pursue complementary outpatient sites. The company maintains a leverage ratio at the low end of its stated range, preserving flexibility for future opportunities.
Medicaid, OB3, and State Supplemental Payments
HCA anticipates a $250 million to $450 million year-over-year decline in net state supplemental payment benefits. Three primary drivers account for this range: a paused Texas program, fewer quarters of benefit from Tennessee, and a Virginia retro payment.
Regarding OB3 Medicaid cuts, management believes 2026 remains largely manageable. Work requirements under OB3 do not take effect until 2027. Furthermore, HCA’s heavy presence in non-expansion states — roughly 60% of revenue — provides meaningful insulation. Non-expansion states face a smaller impact from work requirements and supplemental payment reforms.
Notably, the state of Georgia recently received CMS approval for its Directed Payment Program (DPP). HCA expects to size that benefit at the Q1 2026 earnings call. Additionally, discussions between Florida and CMS are ongoing, though no formal approval has been announced yet.
Outlook for 2026 and Beyond
HCA expects overall volume growth of 2%–3% in 2026. Specifically, Medicare, Medicaid, and commercial volumes (excluding HIX) should all grow within that range. Medicare continues to perform at or above that pace, while Medicaid is recovering as post-redetermination headwinds fade.
Finally, the company remains confident in the durability of its market position. Population growth, demand expansion, and network development across 43 markets provide a stable foundation. Combined with scale advantages in supply chain, labor, and revenue cycle, HCA stands well-positioned to navigate 2026’s challenges and sustain long-term growth.
